Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period-Reference-Cited by-同舟云学术

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period

Published:2010-09-16 Issue:3 Volume:51 Page:622-629
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:

Author:

Cazenave Jean-Pierre,Isola Hervé,Waller Chantal,Mendel Isabelle,Kientz Daniel,Laforêt Michel,Raidot Jean-Pierre,Kandel Gérard,Wiesel Marie-Louise,Corash Laurence

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1537-2995.2010.02873.x/fullpdf

Reference13 articles.

1. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura;Alvarez-Larrán;Vox Sang,2004

2. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura;de la Rubia;Br J Haematol,2001

3. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994-1998;Andreu;Transfusion,2002

4. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen;Cazenave;Vox Sang,2004

5. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set;Janetzko;Transfusion,2005

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet Pathogen Reduction Technology—Should We Stay or Should We Go…?;Journal of Clinical Medicine;2024-09-10

2. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7‐day storage;Transfusion;2023-02-18

3. Health Economic Aspects of Platelet Concentrates: Comparing Cost and Reimbursement of Pathogen Inactivated and Conventional Platelet Concentrates in a German Comprehensive Cancer Center;Oncology Research and Treatment;2023

4. Platelet intrinsic apoptosis;Thrombosis Research;2022-12

5. Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies;Transfusion and Apheresis Science;2022-06